Platelet production in idiopathic thrombocytopenic purpura. 1993

Y Najean, and J D Rain, and V Dufour
Service de Médecine Nucléaire, Hôpital Saint-Louis, Paris, France.

522 patients with chronic thrombocytopenia were studied over a period of three years. 252 of them suffered from idiopathic, acquired, thrombocytopenic purpura with excessive platelet destruction (platelet count less than 50,000 and mean survival less than 3 days). All of these cases were studied by using Indium oxinate labelled autologous platelets. The essential finding in these cases was the absent or only slight reactive hyperproduction, regardless of age and regardless of the severity of platelet destruction. No significant modification in platelet production was observed in the presence or in the absence of anti-platelet antibodies. No significant difference in the haematopoietic response, which was only exceptionally greater than twice the normal value, was observed whether thrombocytopenia was or not very long-standing, very severe, or affected a child or an adult. Megakaryocytosis, assessed on smears or biopsy sections, and the mean platelet volume do not constitute parameters for measuring platelet production. These findings confirm previous findings reported in the 1970s using radioactive chromium as the tracer. They demonstrate that the regulation of megakaryocyte production differs from that of erythropoietic production. They also show that determination of platelet production based on the survival of autologous platelets is able to distinguish between excessive destruction, even in the absence of a haematopoietic response, and defective production, demonstrated when the haematopoietic response is less than 50% of the normal value.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D016553 Purpura, Thrombocytopenic, Idiopathic Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms. Autoimmune Thrombocytopenic Purpura,Idiopathic Thrombocytopenic Purpura,Purpura, Thrombocytopenic, Autoimmune,Werlhof's Disease,Autoimmune Thrombocytopenia,Immune Thrombocytopenia,Immune Thrombocytopenic Purpura,Thrombocytopenic Purpura, Autoimmune,Werlhof Disease,Autoimmune Thrombocytopenias,Autoimmune Thrombocytopenic Purpuras,Disease, Werlhof,Disease, Werlhof's,Idiopathic Thrombocytopenic Purpuras,Immune Thrombocytopenias,Immune Thrombocytopenic Purpuras,Purpura, Autoimmune Thrombocytopenic,Purpura, Idiopathic Thrombocytopenic,Purpura, Immune Thrombocytopenic,Purpuras, Autoimmune Thrombocytopenic,Purpuras, Idiopathic Thrombocytopenic,Purpuras, Immune Thrombocytopenic,Thrombocytopenia, Autoimmune,Thrombocytopenia, Immune,Thrombocytopenias, Autoimmune,Thrombocytopenias, Immune,Thrombocytopenic Purpura, Idiopathic,Thrombocytopenic Purpura, Immune,Thrombocytopenic Purpuras, Idiopathic,Thrombocytopenic Purpuras, Immune,Werlhofs Disease

Related Publications

Y Najean, and J D Rain, and V Dufour
May 1974, British journal of haematology,
Y Najean, and J D Rain, and V Dufour
June 1985, The Journal of the Association of Physicians of India,
Y Najean, and J D Rain, and V Dufour
March 1980, Clinical and experimental immunology,
Y Najean, and J D Rain, and V Dufour
December 1983, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
Y Najean, and J D Rain, and V Dufour
January 1970, Medicina,
Y Najean, and J D Rain, and V Dufour
August 1990, Kaku igaku. The Japanese journal of nuclear medicine,
Y Najean, and J D Rain, and V Dufour
October 1990, Thrombosis research,
Y Najean, and J D Rain, and V Dufour
April 1982, Seminars in thrombosis and hemostasis,
Y Najean, and J D Rain, and V Dufour
June 1985, The Journal of the Association of Physicians of India,
Copied contents to your clipboard!